| Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma A Younes, AK Gopal, SE Smith, SM Ansell, JD Rosenblatt, KJ Savage, ... Journal of clinical oncology 30 (18), 2183-2189, 2012 | 1804 | 2012 |
| Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas A Younes, NL Bartlett, JP Leonard, DA Kennedy, CM Lynch, EL Sievers, ... New England journal of medicine 363 (19), 1812-1821, 2010 | 1660 | 2010 |
| Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse EL Sievers, RA Larson, EA Stadtmauer, E Estey, B Löwenberg, ... Journal of Clinical Oncology 19 (13), 3244-3254, 2001 | 1184 | 2001 |
| Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study B Pro, R Advani, P Brice, NL Bartlett, JD Rosenblatt, T Illidge, J Matous, ... Journal of clinical oncology 30 (18), 2190-2196, 2012 | 1172 | 2012 |
| United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia SL Soignet, SR Frankel, D Douer, MS Tallman, H Kantarjian, E Calleja, ... Journal of Clinical Oncology 19 (18), 3852-3860, 2001 | 1103 | 2001 |
| Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia V Rocha, J Cornish, EL Sievers, A Filipovich, F Locatelli, C Peters, ... Blood, The Journal of the American Society of Hematology 97 (10), 2962-2971, 2001 | 1024 | 2001 |
| The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma PD Senter, EL Sievers Nature biotechnology 30 (7), 631-637, 2012 | 926 | 2012 |
| Antibody-drug conjugates in cancer therapy EL Sievers, PD Senter Annual review of medicine 64 (1), 15-29, 2013 | 919 | 2013 |
| Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a … CH Moskowitz, A Nademanee, T Masszi, E Agura, J Holowiecki, MH Abidi, ... The Lancet 385 (9980), 1853-1862, 2015 | 884 | 2015 |
| Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate: Presented in part at the 1997 … EL Sievers, FR Appelbaum, RT Spielberger, SJ Forman, D Flowers, ... Blood, The Journal of the American Society of Hematology 93 (11), 3678-3684, 1999 | 676 | 1999 |
| Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence RA Larson, EL Sievers, EA Stadtmauer, B Löwenberg, EH Estey, ... Cancer 104 (7), 1442-1452, 2005 | 553 | 2005 |
| Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate NM Okeley, JB Miyamoto, X Zhang, RJ Sanderson, DR Benjamin, ... Clinical Cancer Research 16 (3), 888-897, 2010 | 454 | 2010 |
| A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma A Forero‐Torres, JP Leonard, A Younes, JD Rosenblatt, P Brice, ... British journal of haematology 146 (2), 171-179, 2009 | 325 | 2009 |
| Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) RA Larson, M Boogaerts, E Estey, C Karanes, EA Stadtmauer, EL Sievers, ... Leukemia 16 (9), 1627-1636, 2002 | 316 | 2002 |
| Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL A Chiu, W Xu, B He, SR Dillon, JA Gross, E Sievers, X Qiao, P Santini, ... Blood 109 (2), 729-739, 2007 | 308 | 2007 |
| Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma AK Gopal, R Chen, SE Smith, SM Ansell, JD Rosenblatt, KJ Savage, ... Blood, The Journal of the American Society of Hematology 125 (8), 1236-1243, 2015 | 290 | 2015 |
| TTI-621 (SIRPαFc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding PS Petrova, NN Viller, M Wong, X Pang, GHY Lin, K Dodge, V Chai, ... Clinical cancer research 23 (4), 1068-1079, 2017 | 283 | 2017 |
| Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy P Rajvanshi, HM Shulman, EL Sievers, GB McDonald Blood, The Journal of the American Society of Hematology 99 (7), 2310-2314, 2002 | 279 | 2002 |
| A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies MA Fanale, A Forero-Torres, JD Rosenblatt, RH Advani, AR Franklin, ... Clinical Cancer Research 18 (1), 248-255, 2012 | 260 | 2012 |
| Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia EL Sievers, BJ Lange, TA Alonzo, RB Gerbing, ID Bernstein, FO Smith, ... Blood, The Journal of the American Society of Hematology 101 (9), 3398-3406, 2003 | 244 | 2003 |